Allderma

Allderma focuses on the marketing and sale of over-the-counter and self-care dermatology products in the Nordic region. Their lead product, Terclara (containing terbinafin), is marketed as a topical treatment for mild to moderate onychomycosis (nail fungus) and has demonstrated efficacy comparable to oral antifungals without the same risk for systemic side effects. Terclara is available in Sweden and, as of 2025, in Norway, following positive findings from large Phase 3 trials of the active molecule (MOB-015/terbinafin) involving over 800 patients, showing potential to become a future market leader in nail fungus treatment.